ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings
ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 关于公司CEO增持股票收益权暨控股股东减持股份的公告 | 2021-07-20 | Chinese | |
| 睿智医药：2021年第二次临时股东大会法律意见书 | 2021-07-13 | Chinese | |
| 2021年第二次临时股东大会决议公告 | 2021-07-13 | Chinese | |
| 独立董事关于第四届董事会第三十六次会议相关事项的独立意见 | 2021-07-08 | Chinese | |
| 关于聘任华风茂先生为公司首席执行官CEO（总经理）及曾宪维先生职务变动的公告 | 2021-07-08 | Chinese | |
| 第四届董事会第三十六次会议决议公告 | 2021-07-08 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2021
15 filings
| |||||
| 36035739 | 关于公司CEO增持股票收益权暨控股股东减持股份的公告 | 2021-07-20 | Chinese | ||
| 36035725 | 睿智医药：2021年第二次临时股东大会法律意见书 | 2021-07-13 | Chinese | ||
| 36035713 | 2021年第二次临时股东大会决议公告 | 2021-07-13 | Chinese | ||
| 36035704 | 独立董事关于第四届董事会第三十六次会议相关事项的独立意见 | 2021-07-08 | Chinese | ||
| 36035694 | 关于聘任华风茂先生为公司首席执行官CEO（总经理）及曾宪维先生职务变动的公告 | 2021-07-08 | Chinese | ||
| 36035679 | 第四届董事会第三十六次会议决议公告 | 2021-07-08 | Chinese | ||
| 36035669 | 关于回购公司股份的进展公告 | 2021-07-01 | Chinese | ||
| 36035663 | 广发证券关于睿智医药发行股份及支付现金购买资产暨关联交易之限售股份流通上市的核查意见 | 2021-06-30 | Chinese | ||
| 36035647 | 关于重大资产重组部分限售股份上市流通的提示性公告 | 2021-06-30 | Chinese | ||
| 36035597 | 上海睿智化学研究有限公司90%股权减值测试报告及专项审核报告 | 2021-06-25 | Chinese | ||
| 36035585 | 独立董事关于第四届董事会第三十五次会议相关事项的事前认可意见 | 2021-06-25 | Chinese | ||
| 36035577 | 睿智医药科技股份有限公司拟对并购上海睿智化学研究有限公司所形成的商誉进行减值测试涉及的相关资产组可收回金额的资产评估报告 | 2021-06-25 | Chinese | ||
| 36035554 | 关于发行股份及支付现金购买资产之标的公司业绩承诺期限届满减值测试情况的公告 | 2021-06-25 | Chinese | ||
| 36035543 | 关于计提商誉减值准备的补充公告 | 2021-06-25 | Chinese | ||
| 36035532 | 独立董事关于第四届董事会第三十五次会议相关事项的独立意见 | 2021-06-25 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
ChemPartner PharmaTech Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55161/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55161 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55161 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55161 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55161}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ChemPartner PharmaTech Co., Ltd. (id: 55161)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.